Medicare Enrolled
Dr. Catherine Kuntz, M.D.
Pulmonary Disease · Wynnewood, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kuntz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kuntz?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kuntz
Dr. Catherine Kuntz is a pulmonary disease specialist in Wynnewood, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kuntz performed 1,760 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Kuntz received a total of $7,009 from 43 pharmaceutical and/or device companies across 285 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kuntz is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 14% volume in PA
$7,009 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗1,760
Medicare services
Top 14% in PA for pulmonary disease
Not available
Unique patients (not deduplicated)
$98
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
388 | $178 | $325 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
290 | $22 | $78 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
221 | $99 | $144 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
182 | $147 | $240 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
143 | $105 | $170 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
142 | $66 | $95 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
101 | $145 | $270 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
57 | $15 | $30 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
43 | $7 | $35 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
36 | $8 | $45 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
35 | $9 | $35 |
| New patient office visit, complex (60-74 min) | 33 | $171 | $325 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
22 | $17 | $30 |
| Lung cancer screening counseling visit A visit to discuss the need for lung cancer screening using a low-dose CT scan. This service is used to determine eligibility and facilitate shared decision making. |
22 | $30 | $45 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
16 | $16 | $20 |
| Sedation by physician, initial 15 minutes Administration of a drug to induce depression of consciousness by the physician performing a procedure. This code covers the initial 15 minutes of sedation for patients aged 5 years or older. |
15 | $10 | $70 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
14 | $72 | $120 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$7,009
Total received (2018-2024)
Avg $1,001/year across 7 years
Top 24% in PA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
285
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,411
2023
$1,490
2022
$1,219
2021
$636
2020
$303
2019
$1,078
2018
$872
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$362
GlaxoSmithKline, LLC.
$268
GENZYME CORPORATION
$228
Mylan Specialty L.P.
$145
Amgen Inc.
$79
Insmed, Inc.
$70
Electromed, Inc.
$45
Takeda Pharmaceuticals U.S.A., Inc.
$44
Regeneron Healthcare Solutions, Inc.
$35
United Therapeutics Corporation
$26
ABBVIE INC.
$25
Novartis Pharmaceuticals Corporation
$24
Alexion Pharmaceuticals, Inc.
$24
Merck Sharp & Dohme LLC
$21
Philips North America LLC
$16
Top 3 companies account for 60.8% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,509
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,387
GlaxoSmithKline, LLC.
$607
GENZYME CORPORATION
$529
Mylan Specialty L.P.
$526
Genentech USA, Inc.
$355
Insmed, Inc.
$235
Philips Electronics North America Corporation
$180
COMSORT, Inc
$150
Regeneron Healthcare Solutions, Inc.
$130
Takeda Pharmaceuticals U.S.A., Inc.
$110
Actelion Pharmaceuticals US, Inc.
$109
Novartis Pharmaceuticals Corporation
$102
Amgen Inc.
$95
Exeltis, USA Inc.
$75
Mallinckrodt Hospital Products Inc.
$74
United Therapeutics Corporation
$73
E.R. Squibb & Sons, L.L.C.
$54
Pulmonx Corporation
$49
Grifols USA, LLC
$48
ANI Pharmaceuticals, Inc.
$46
Bayer HealthCare Pharmaceuticals Inc.
$46
Covis Pharma GmBH
$45
Electromed, Inc.
$45
Merck Sharp & Dohme LLC
$44
JAZZ PHARMACEUTICALS INC.
$31
Circassia Pharmaceuticals Inc
$28
Mallinckrodt Enterprises LLC
$26
ABBVIE INC.
$25
Alexion Pharmaceuticals, Inc.
$24
Allergan Inc.
$23
Merck Sharp & Dohme Corporation
$23
Mallinckrodt LLC
$22
Inogen, Inc.
$21
Kaleo, Inc.
$20
AbbVie Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$19
Boston Scientific Corporation
$19
Teva Pharmaceuticals USA, Inc.
$18
Sunovion Pharmaceuticals Inc.
$18
Celgene Corporation
$17
Philips North America LLC
$16
Resmed Corp
$16
Top 3 companies account for 50.0% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (9687) Lunoa 2 0 · (AK6) Vest Therapy · ACTHAR · AFINITOR · AIRSUPRA · ALVESCO · ARALAST · AREXVY · ASMANEX · AUVI-Q · Abraxane · Adempas · Arikayce · Astral · BEVESPI AEROSPHERE · BREZTRI · CINQAIR · DALVANCE · DUAKLIR PRESSAIR · DUPIXENT · ELIQUIS · Esbriet · FASENRA · GLASSIA · IMFINZI · INOGEN ONE G3 OXYGEN CONCENTRATOR · KISQALI · NUCALA · OFEV · OPDIVO · OPSUMIT · OPSUMIT MACITENTAN · PURIFIED CORTROPHIN GEL · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · ULTOMIRIS · UPTRAVI · Utibron · WINREVAIR · Wellcentive Undiv · XOLAIR · Xolair · YUPELRI · Yupelri · ZERBAXA · inCourage
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Pulmonary diseases in nearby ZIP areas
264
County median income
$111,521
Nearest hospital to ZIP centroid (approximate)
MAIN LINE HOSPITAL LANKENAU
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kuntz is a clinical cardiology specialist, with above-average Medicare volume (top 14% in PA), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kuntz experienced with critical care, first 30-74 min?
Based on Medicare claims data, Dr. Kuntz performed 388 critical care, first 30-74 min services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Kuntz receive payments from pharmaceutical companies?
Yes. Dr. Kuntz received a total of $7,009 from 43 companies across 285 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kuntz's costs compare to other pulmonary diseases in Wynnewood?
Dr. Kuntz's average Medicare payment per service is $98. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kuntz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Wynnewood
Browse pulmonary diseases in Wynnewood ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in PA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in PA
Which PA pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology